Back to Search Start Over

Chitosan Derivative-Based Microspheres Loaded with Fibroblast Growth Factor for the Treatment of Diabetes.

Authors :
Wu, Jue
Chen, Qian
Wang, Wenfei
Lin, Yuhong
Kang, Hong
Jin, Zheng
Zhao, Kai
Source :
Polymers (20734360). Jul2023, Vol. 15 Issue 14, p3099. 14p.
Publication Year :
2023

Abstract

Diabetes mellitus type 2 (T2DM) is a disease caused by genetic and environmental factors, and the main clinical manifestation is hyperglycemia. Currently, insulin injections are still the first-line treatment for diabetes. However, repeated injections may cause insulin resistance, hypoglycemia, and other serious side effects. Thus, it is imperative to develop new diabetes treatments. Protein-based diabetes drugs, such as fibroblast growth factor-21 (FGF-21), have a longer-lasting glycemic modulating effect with high biosafety. However, the instability of these protein drugs limits their applications. In this study, we extract protein hypoglycemic drugs with oral and injectable functions. The FGF-21 analog (NA-FGF) was loaded into the chitosan derivative-based nanomaterials, N-2-Hydroxypropyl trimethyl ammonium chloride chitosan/carboxymethyl chitosan (N-2-HACC/CMCS), to prepare NA-FGF-loaded N-2-HACC/CMCS microspheres (NA-FGF-N-2-HACC/CMCS MPs). It was well demonstrated that NA-FGF-N-2-HACC/CMCS MPs have great biocompatibility, biostability, and durable drug-release ability. In addition to injectable drug delivery, our prepared microspheres were highly advantageous for oral administration. The in vitro and in vivo experimental results suggested that NA-FGF-N-2-HACC/CMCS MPs could be used as a promising candidate and universal nano-delivery system for both oral and injectable hypoglycemic regulation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20734360
Volume :
15
Issue :
14
Database :
Academic Search Index
Journal :
Polymers (20734360)
Publication Type :
Academic Journal
Accession number :
169702006
Full Text :
https://doi.org/10.3390/polym15143099